NCT05751733: Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST |
|
|
| Recruiting | N/A | 258 | RoW | Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib | Xiangya Hospital of Central South University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Gastrointestinal Stromal Tumors | 01/26 | 01/27 | | |
